Allergic conjunctivitis cost-effectiveness of therapy: Difference between revisions
| Line 2: | Line 2: | ||
{{Allergic conjunctivitis}} | {{Allergic conjunctivitis}} | ||
==Overview== | ==Overview== | ||
[[Allergic]] [[conjunctivitis]] is a common, [[chronic]] condition associated with significant ongoing out-of-pocket expenses and [[health]] care costs. | |||
==Cost-effectiveness of [[therapy]]== | ==Cost-effectiveness of [[therapy]]== | ||
===[[Olopatadine]]=== | ===[[Olopatadine]]=== | ||
Revision as of 04:44, 30 August 2022
|
Allergic conjunctivitis Microchapters |
|
Diagnosis |
|---|
|
Treatment |
|
Case Studies |
|
Allergic conjunctivitis cost-effectiveness of therapy On the Web |
|
American Roentgen Ray Society Images of Allergic conjunctivitis cost-effectiveness of therapy |
|
FDA on Allergic conjunctivitis cost-effectiveness of therapy |
|
CDC on Allergic conjunctivitis cost-effectiveness of therapy |
|
Allergic conjunctivitis cost-effectiveness of therapy in the news |
|
Blogs on Allergic conjunctivitis cost-effectiveness of therapy |
|
Risk calculators and risk factors for Allergic conjunctivitis cost-effectiveness of therapy |
Overview
Allergic conjunctivitis is a common, chronic condition associated with significant ongoing out-of-pocket expenses and health care costs.
Cost-effectiveness of therapy
Olopatadine
Given its higher efficacy, it could save a significant proportion of relapse direct costs in a range of European settings[1].
Emedastine
It was found to be economically dominant i.e. more effective and less expensive in terms of first-line treatment failure, including visits, drugs and laboratory examinations[2].
References
- ↑ Lafuma A, Smith AF (2002). "Cost-effectiveness of olopatadine in seasonal allergic conjunctivitis treatment". Expert Rev Pharmacoecon Outcomes Res. 2 (6): 549–54. doi:10.1586/14737167.2.6.549. PMID 19807479.
- ↑ Pinto CG, Lafuma A, Fagnani F, Nuijten MJ, Berdeaux G (2001). "Cost effectiveness of emedastine versus levocabastine in the treatment of allergic conjunctivitis in 7 European countries". Pharmacoeconomics. 19 (3): 255–65. doi:10.2165/00019053-200119030-00004. PMID 11303414.